Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
Agios Pharmaceuticals, a leader in rare disease therapies, will present at the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agios Pharmaceuticals, a leader in rare disease therapies, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT. The presentation will be accessible via a live webcast on the company’s website, with a replay available for at least two weeks afterward. Agios markets a first-in-class pyruvate kinase activator and is advancing a clinical pipeline focused on diseases like sickle cell disease and thalassemia. For more information, visit www.agios.com.
Details
News Market Reaction – AGIO
The recorded move for AGIO in the trading session of this news was +0.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.
Contacts
Investors:
Adam Bero, Kendall IR
abero@kendallir.com
Media:
Jessica Rennekamp
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.